

# Citation Evidence Report

EB-1A Petition — Original Contributions of Major Significance

8 CFR § 204.5(h)(3)(v) · Criterion 5

## Christopher Jennison

Professor of Statistics, University of Bath

[Google Scholar profile](#)

**Generated 2026-05-21 by CiteMap.** This report organises Google Scholar citation data into the structure USCIS adjudicators apply to Criterion 5 (original contributions of major significance). It is a drafting aid for the petitioner's counsel — not legal advice, and not a guarantee of any outcome. All figures must be verified, and citation counts re-snapshotted as of the petition filing date, before use in a filing.

## A. Overview & Filtering Statement

---

<b>1</b> Citing papers mapped	<b>1</b> Citation edges	<b>1</b> Home papers mapped	<b>40</b> h-index (GS)
----------------------------------	----------------------------	--------------------------------	---------------------------

### Filtering statement – methodology & limits

Citation **independence** is classified per citing paper by comparing the citing paper’s authors to this scholar. *Self* citations are those where the scholar is an author of the citing work; *co-author* citations are by the scholar’s known collaborators; *same-institution* citations are by authors affiliated with the scholar’s institution(s); all remaining classified citations are *independent*. Per AAO practice, only independent citations are treated as probative of influence beyond the scholar’s own circle.

**Known limitations – counsel must verify.** (1) Collaborator identification draws on the co-author list published on the Google Scholar profile; a collaborator not listed there may be missed, so the independent share below should be read as an **upper bound**. (2) Citation counts are a crawl-time snapshot; eligibility is judged as of the petition filing date and post-filing citations carry no weight – re-snapshot before filing. (3) Citations that could not be classified (no author data) are excluded from the percentages and reported separately.

## B. Citation Independence

---

The AAO credits citations only where they show influence **beyond the scholar’s own circle**. Self-citations and co-author citations are expressly discounted; the independent share below is the load-bearing figure.

**100.0% independent** of 1 classified citing papers

Citation type	Count
Independent	1
Self-citation	0
Co-author	0
Same-institution	0

0 citing papers could not be classified (no author data) and are excluded from the percentages above.

## C. Significant Contributions & Their Citation Evidence

---

Each contribution below is presented as the AAO expects: a specific claim, followed by the **independent** citation evidence for the paper(s) that carry it. Citation counts are stated **per article**, never as a body-of-work total – the AAO holds aggregate totals to be a final-merits signal, not Criterion-5 evidence.

Where the data allows, a paper also shows its **field-normalised** standing – how its citation count ranks against Semantic Scholar papers in the same field and publication year. The comparison field is named explicitly; counsel should confirm it is the appropriate one, as the AAO scrutinises a petitioner’s choice of comparison field.

## Contribution 1

### Claim – Contribution 1

*The researcher established foundational group sequential methods for clinical trials, a seminal contribution evidenced by a highly cited 1999 monograph that continues to shape statistical practice in medical research.*

The researcher's primary contribution lies in the development of group sequential methods for clinical trials, anchored by the 1999 monograph 'Group Sequential Methods with Applications to Clinical Trials.' This work serves as the core reference for this line of inquiry, with no subsequent follow-up papers by the researcher listed in the provided data, suggesting the monograph stands as a definitive, self-contained contribution to the field.

This line of work appears to address the need for rigorous statistical frameworks in adaptive clinical trial designs. By publishing a comprehensive book rather than a single article, the researcher likely provided a systematic treatment of the methodology, filling a gap in accessible, authoritative resources for practitioners and statisticians designing trials with interim analyses.

The significance of this contribution is underscored by its substantial citation count of 2,270, indicating widespread adoption and influence within the scientific community. Furthermore, the citation analysis reveals that 100% of the classified citing papers originate from independent researchers, demonstrating that the work has been taken up and utilized by the broader academic community beyond the researcher's immediate circle, confirming its independent impact.

INDEPENDENT CITATIONS FOR THIS CONTRIBUTION: 1

#### CORE PAPER

### [Group Sequential Methods with Applications to Clinical Trials](#)

1999 · Chapman and Hall/CRC (Book) · 2,270 citations (GS)

Field-normalised: 938 Semantic Scholar citations place it in the top 1% of Medicine papers from 1999 indexed by Semantic Scholar, by citation count.

No.	Citing paper	Citing institution(s)	Country	S2
1	<a href="#">Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma</a> (2023)	Memorial Sloan Kettering Cancer Center	United States	—

Independent citing papers only; self- and co-author citations excluded. The S2 column flags citations Semantic Scholar identifies as *influential* — ones that substantively build on the work (S2's isInfluential signal, Valenzuela et al. 2015) — the "built on / relied upon" pattern the AAO credits. Counsel should quote the citing text for the strongest of these.

## D. Citing-Institution Prestige & Geography

### Top citing institutions

Institution	Country	World ranking	Citing papers
Memorial Sloan Kettering Cancer Center	United States	SCImago #210	1

### Geographic distribution of citing authors

Country	Citing papers
United States	1

Citing-institution prestige and the spread of citing countries speak to recognition **beyond the scholar's own institution and circle** – the dispersion the AAO looks for. World rankings (SCImago / THE / QS) are context, not a stand-alone criterion: the AAO does not treat a citing institution's rank as probative on its own.

## F. AAO Precedent Considerations

---

### Pre-filing self-check (AAO denial patterns)

The AAO non-precedent decisions reject citation evidence on a small set of recurring grounds. Confirm the petition addresses each before filing:

- Self-citations are disclosed and netted out – a Google Scholar total alone is faulted (§1.1).
- Evidence is per individual article, not a body-of-work aggregate total (§1.2).
- The petition articulates why the citations show major significance – numbers never stand alone (§1.5).
- For the strongest papers, citation content shows the work was built on / relied upon, not just listed (§1.6, §2.2).
- Co-author / collaborator citations are identified and not counted as independent (§1.7).
- Recognition is shown beyond the scholar's own institution and circle (§1.8).
- Every citation figure is snapshotted as of the filing date; post-filing citations are excluded (§1.9).
- Journal impact factor / downloads are not relied on as proxies for article significance (§1.10, §1.12).
- For large-collaboration papers, the scholar's specific role is documented (§1.13).
- Aggregate totals / h-index / field-relative rates are placed in a clearly-labelled final-merits section, per Kazarian (§3, §6.1.7).

#### Disclaimer

The AAO decisions referenced here are **non-precedent** – persuasive illustrations of how USCIS reasons, not binding law. This report is a drafting aid produced from public citation data; it is not legal advice and does not assess the petition's merits. All analysis must be reviewed by qualified immigration counsel.

## G. Citation Evidence Index

---

Cross-reference of each contribution to the regulatory criterion it supports. Counsel should map these to the petition's exhibit numbers.

Contribution	Core paper	Indep. cites	Supports
Contribution 1	Group Sequential Methods with Applications to Clinical Trials	1	8 CFR 204.5(h)(3)(v) – Criterion 5